Report Options 

 

 

 

 

NGS Leaders 

Date published June 2011

 

Additional info Single-site, country, and global licenses are multi-user, searchable, and cut-and-paste ready PDFs delivered by e-mail.

For Corporate Subscriptions, Multi-Reports Orders, Discounts or Order Questions.  

Contact:
Kerri Kelley
Customer Service
781-972-1347 


IPR-Bundle-Button 

Next Generation Sequencing Generates Momentum: Markets Respond to Technology and Innovation Advances - Overview

Author: Ken Rubenstein, PhD

Report Brochure Cover ImageThis report focuses on current and innovative NGS technologies, services and markets to answer such questions as;

 

 

  • Which early NGS market entrants have been continually improving and updating their original systems? 
  • Who has introduced new scaled-down instruments to broaden the market? 
  • What Generation 2.5 systems featuring new detection technologies and single-molecule sequencing are now on the market?
  • When will third generation of instruments led by nanopore technologies be entering the commercial feasibility stage?
  • Why upstream sample handling is undergoing continual technological innovation?
  • Which informatics providers are moving rapidly toward fully integrated systems to provide the rapid generation of actionable biological information?

 

Next Generation Sequencing Generates Momentum: Markets Respond to Technology and Innovation Advances describes these innovations and analyzes their impact on this extremely dynamic technology and market sector. We report on the:

  • NGS systems on the market and those on the horizon
  • Possible game changing innovations still in development 
  • NGS market dynamics for instruments and services
  • Results of an Insight Pharma Reports’ user market survey 
  • Interviews with six experts on diverse aspects of NGS 
  • Analysis on how the field will likely develop over the next several years.

 

Next Generation Sequencing Generates Momentum: Markets Respond to Technology and Innovation Advances updates the product offerings from Roche/454, Illumina, Life Technologies (Ion Torrent), Complete Genomics (CGI), Helicos, Pacific Biosciences (PacBio).  As well as NGS upstream sample preparation and downstream informatics, aspects of NGS that have developed into substantial and fast-growing markets of their own. Companies in the informatics space covered in this report include Geospiza, Accelrys, GenoLogics, CLC bio, GenomeQuest, Partek, and DNAStar and Ingenuity Systems.

Next Generation Sequencing Generates Momentum: Markets Respond to Technology and Innovation Advances looks at a number of new product and technology candidates in varying stages of development. As the report highlights, some candidates are mainly extensions of current technologies, while others represent something very different.  

Large companies have entered the new technology race such as General Electric, IBM as well as Life Technologies with its Starlight system.  Many small entrepreneurial companies are also covered in this report including GnuBio’s with its microreactors, Halcyon Molecular and ZS Genetics’ use of scanning transmission electron microscopy, Intelligent Bio-Systems’ 40 million five micron wells, NABsys, using a hybridization-assisted nanopore method, NobleGen’s approach involving preliminary replacement of each base by longer oligonucleotides prior to sequencing and LightSpeed Genomics where patents suggest involving novel optical scanning methodology.

Next Generation Sequencing Generates Momentum: Markets Respond to Technology and Innovation Advances investigates the market dynamics where Illumina, Life Technologies, and Roche currently dominate a sequencer market now estimated to exceed $1 billion per year.  It’s a market where companies are making continual advances in cost and performance at a pace exceeding that associated with semiconductor technology, where market adoption, application diversity, and implications for life science research continue to advance.

  • Learn from this report the answers to such questions as:
  • Why is Illumina the clear market leader, accounting for about 60% of revenues? 
  • Who are the key players in the NGS services market for now? 
  • What’s attractive about Pacific Biosciences’ single-molecule sequencer?
  • What will be the impact of low-cost systems?
  • Will the market expand into clinical diagnostic applications?

 

About the Author
Ken Rubenstein, PhD
, a biochemist and molecular biologist, received his PhD at the University of Wisconsin and postdoctoral training at the University Of Pennsylvania School Of Medicine. He was a key innovator and research manager for Syva Company, the diagnostics branch of Syntex Corporation. During his 13 years with Syva, Dr. Rubenstein became vice president, scientific affairs, and a function that included strategic planning. Since 1983, he has served as a technology and marketing consultant to biomedical companies and an industry analyst, with more than 40 published studies to his credit.